Assessment of a Brief Post Traumatic Stress Disorder Intervention for Use in Botswana

July 27, 2025 updated by: Keneilwe Molebatsi, University of Botswana

The Efficacy, Feasibility, and Acceptability of a Culturally Adapted Brief Intervention for Post-Traumatic Stress Disorder in Severe Mental Illness

The purpose of this study is to culturally adapt a brief psychological intervention for Post-Traumatic Stress Disorder (PTSD) and assess its efficacy, feasibility, and acceptability in a pilot trial. The intervention has been shown to be efficacious among individuals with comorbid severe mental illness (SMI) and PTSD.

The study will be conducted in three phases. The first phase will determine a description of trauma and responses to traumatic experiences among patients with severe mental illness. The first phase of the study will also determine participants' and mental health care providers' perceptions of suitable PTSD interventions in this middle-income context. The findings will then be used to culturally adapt the brief intervention in the second phase. A pilot trial will be conducted in the third phase of the study.

Participants with comorbid SMI and PTSD will be randomized into two groups (n= 20 intervention group, n= 20 control group). Outcomes of the intervention such as the severity of PTSD symptoms, knowledge about PTSD will be assessed at baseline and at different timelines during the study.

This study will fill the knowledge gap on trauma and its consequences among individuals with severe mental illness in Botswana, it will also contribute to the improvement of clinical practice in the management of PTSD and SMI.

Study Overview

Detailed Description

Study participants will be recruited from Sbrana Psychiatric Hospital, the only referral psychiatric hospital in Botswana. The hospital population is representative of the culturally diverse Botswana nation because patients with severe mental illness from the entire country are admitted to the hospital. Forty participants (40) will be recruited and randomized to receive the Brief Relaxation, Education, And Trauma HEaling (BREATHE) intervention or treatment as usual.

The intervention will be delivered by the Principal Investigator who has received training from the intervention developer. Supervision will be provided telephonically.

The BREATHE intervention will be delivered weekly for each participant for a total of three weeks and 4 participants will be enrolled per group resulting in a total of 5 groups. The estimated period of intervention delivery and data collection is therefore expected to last for a period of ~15 weeks.

Outcomes such as anxiety, depressive and PTSD Symptoms, and knowledge about PTSD will be assessed before participants receive the intervention, weekly (following each treatment session), month one and month three after treatment completion. Assessment of feasibility and acceptability will be done at treatment completion with the intervention group. Participants on the control arm will receive outcome measures at the same time points as those receiving the intervention. The investigators will utilize an objective assessment of skin conductance which has been shown to be greater in individuals with PTSD than in individuals without PTSD and similarly increased during a trauma interview in individuals with PTSD compared to individuals who do not have PTSD.

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Keneilwe Molebatsi, MMED (Psychiatry)
  • Phone Number: +26777458378
  • Email: molebatsik@ub.ac..bw

Study Contact Backup

Study Locations

      • Lobatse, Botswana, 0000
        • Recruiting
        • Sbrana Psychiatric Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Able to understand Setswana or English
  • The patient must meet the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for any SMI as categorized for this study (schizophrenia, schizophreniform disorder, schizoaffective disorder, bipolar mood disorder, and severe depressive disorder)
  • The patient should meet the criteria for Post-Traumatic Stress Disorder as assessed with the Post Traumatic Checklist-5 (PCL-5)

Exclusion Criteria:

  • Currently engaged in psychotherapy for PTSD
  • On pharmacotherapy management of PTSD (to control for medication effects on PTSD symptoms)
  • Inability to understand informed consent
  • Inability to respond to interview questions
  • Patients who have suicidal ideation and history of a suicide attempt within the past 6 months

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention group
Participants will receive the BREATHE intervention for three weeks
A three-week psychological intervention for PTSD which comprise psychoeducation and breathing retraining to manage anxiety symptoms
No Intervention: Control group
The participants will receive treatment as usual

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Post Traumatic Checklist-5
Time Frame: baseline, week 1, 2 ,3,
Mean Change from Baseline in the severity of PTSD symptoms as assessed with the PCL-5. Total scores for the Post Traumatic Checklist-5 range between 0 and 80 with a cut off score of 33 or higher suggesting the patient may benefit from PTSD treatment. Patients with scores lower than 33 may indicate the patient has sub-threshold symptoms of PTSD
baseline, week 1, 2 ,3,
eSense EDA skin conductance device
Time Frame: baseline, week 1, 2 ,3,
Change in physiological arousal as measured with sensors to assess skin conductance
baseline, week 1, 2 ,3,
Mini International Neuropsychiatric Interview (MINI) Plus
Time Frame: baseline, week 3, one month and three months post intervention
Assessment of symptoms meeting the criteria for PTSD
baseline, week 3, one month and three months post intervention
Consent rates
Time Frame: week 3
to assess the acceptability of the intervention by dividing the number of participants who meet the criteria for PTSD and meet the inclusion criteria for the pilot trial by the number of those who consent to participate in the trial
week 3
Adherence rates
Time Frame: week 3
to assess acceptability; measured by the total number of sessions attended by the participants and the reasons for non-adherence.
week 3
knowledge of PTSD scale (KPTSD)
Time Frame: baseline, week 1, 2 ,3, one month and three months post intervention
mean difference in the scores obtained in the knowledge of PTSD scale. Higher scores indicate more knowledge of PTSD.
baseline, week 1, 2 ,3, one month and three months post intervention
Acceptability of Intervention measure (AIM)
Time Frame: week 3
Calculation of scores in the Acceptability of Intervention measure. Higher scores indicate greater acceptability
week 3
Feasibility of Intervention Measure (FIM)
Time Frame: week 3
calculation of scores in the Feasibility of Intervention Measure. Higher scores indicate greater feasibility
week 3
Patient satisfaction scale
Time Frame: week 3
calculation of scores in the satisfaction scale. Higher satisfaction with the intervention will be indicated by high scores on the patient satisfaction scale
week 3

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Health Questionnaire-9 (PHQ-9)
Time Frame: baseline, week 1, 2 ,3, one month and three months post intervention
Mean Change from Baseline in the severity of depressive symptoms as assessed with the PHQ-9
baseline, week 1, 2 ,3, one month and three months post intervention
Clinical Outcomes in Routine Evaluation-Outcome Measure
Time Frame: baseline, week 3, one month and three months post intervention
Mean difference from Baseline in the severity of psychological distress
baseline, week 3, one month and three months post intervention
Zung self-rating anxiety scale
Time Frame: baseline, week 1, 2 ,3, one month and three months post intervention
Mean Change from Baseline in the severity of anxiety symptoms as assessed with the Zung anxiety rating scale. Total scores in the Zung self rating scale range from 20 to 80, with scores above 26 indicating severe and extremely severe anxiety.
baseline, week 1, 2 ,3, one month and three months post intervention
Post Traumatic Checklist-5
Time Frame: one month and three months post intervention
Mean Change from Baseline in the severity of PTSD symptoms as assessed with the Post Traumatic Checklist-5. A five points difference in the total score is an indication that a patient has responded to treatment and 10 points has been determined as a minimum threshold for determining whether the improvement has clinical utility
one month and three months post intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Keneilwe Molebatsi, MMED (Psych), University of Botswana

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 8, 2020

Primary Completion (Estimated)

August 30, 2025

Study Completion (Estimated)

August 30, 2025

Study Registration Dates

First Submitted

June 7, 2020

First Submitted That Met QC Criteria

June 7, 2020

First Posted (Actual)

June 11, 2020

Study Record Updates

Last Update Posted (Actual)

July 30, 2025

Last Update Submitted That Met QC Criteria

July 27, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • UBR/RES/IRB/BIO/179

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The study will be conducted in fulfillment of a Doctor of Philosophy in Psychiatry degree. De-identified data will be shared with the supervisors

IPD Sharing Time Frame

Throughout the study period and one year after completion of write-up

IPD Sharing Access Criteria

de-identified coded data will be stored and shared as a statistical package for the social sciences (SPSS) file.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Traumatic Stress Disorder

Clinical Trials on Brief Relaxation, Education And Trauma HEaling

Subscribe